Development of a novel model for accurate prediction of secondary

Background: Given the increased risk factors such as the wide application of various dose forms of corticosteroids and broad-spectrum antibiotics in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in recent years, the incidence of invasive Methods: Clinical data of 164 hospitalized patients with AECOPD who received treatment in the department of respiratory medicine of Yiwu Central Hospital between January 2022 and January 2024 were reviewed retrospectively, including the diagnosis, gender, age, BMI, use of inhaled corticosteroids, the duration of using antibiotics, use of carbapenem antibiotics, random blood glucose, albumin level, the presence or absence of cerebral infarction aspiration, cancer chemoradiotherapy, complicated cardiovascular disease, procalcitonin level, pulmonary function grade, and surviving time. Data were treated and analyzed by R language statistical software. Results: Of the 164 AECOPD patients, 87 were male and 77 were female, with a mean age of 77.28 ± 8.10 years. The model group consisted of 127 AECOPD patients, including 64 with candidiasis secondary to AECOPD and 63 with no candida infection; the validation group consisted of 37 patients, including 14 with secondary candidiasis and 23 with no Conclusion: The result demonstrated that this new model could accurately predict the occurrence of secondary candidiasis in AECOPD patients, with an accuracy rate of 84%, thus providing a simple and accurate tool for predicting the probability of secondary candidiasis in AECOPD patients, especially in cancer patients complicated with AECOPD. This model can only be used as an auxiliary assessment tool for the possibility of secondary